This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Rheumatoid arthritis
  • /
  • A randomised, double-blind, phase III study compar...
Journal

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.

Read time: 1 mins
Published:1st Jan 2017
Author: Choe JY, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, Baranauskaite A et al.
Availability: Free full text
Ref.:Ann Rheum Dis. 2017;76(1):58-64.
DOI:10.1136/annrheumdis-2015-207764
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest